Please use this identifier to cite or link to this item:
Title: Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Authors: Alcaraz, Antonio
Carballido-Rodríguez, Joaquín
Unda-Urzaiz, Miguel
Medina-López, Rafael
Ruiz-Cerdá, José L
Rodríguez-Rubio, Federico
García-Rojo, Darío
Brenes-Bermúdez, Francisco J
Cózar-Olmo, José M
Baena-González, Víctor
Manasanch, José
Keywords: BII;BPH;IPSS;LUTS;Quality of life;Real-life practice
metadata.dc.subject.mesh: 5-alpha Reductase Inhibitors
Adrenergic alpha-Antagonists
Drug Therapy, Combination
Longitudinal Studies
Lower Urinary Tract Symptoms
Middle Aged
Plant Extracts
Prospective Studies
Prostatic Hyperplasia
Quality of Life
Severity of Illness Index
Watchful Waiting
Issue Date: 25-Jan-2016
Abstract: To evaluate change in quality of life (QoL) and symptoms in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in conditions of current clinical practice. Prospective, longitudinal, multicenter open-label study was carried out in urology outpatient clinics. Patients were ≥40 years of age with an International Prostate Symptom Score (IPSS) score ≥ 8. QoL and symptoms were measured at baseline and 6 months using the Benign Prostatic Hyperplasia Impact Index (BII) and the IPSS. 1713 patients were included for analysis. Mean (SD) IPSS and BII scores at baseline were 16.8 (5.4) and 6.8 (2.6), respectively. 8.9 % (n = 153) of study participants did not receive treatment (watchful waiting, WW), 70.3 % (n = 1204) were prescribed monotherapy (alpha-adrenergic blockers [AB]; phytotherapy [PT, of which 95.2 % was the hexanic extract of Serenoa repens, HESr]; or 5-alpha-reductase inhibitors [5ARI]), and 20.8 % (n = 356) received combined treatment (AB + 5ARI; AB + HESr; others). At 6 months, improvements in QoL were similar across the different medical treatment (MT) groups, both for monotherapy (AB: mean improvement [SD] of 2.4 points [2.4]; PT: 1.9 [2.4]; 5ARI: 2.5 [2.3]) and combined therapy (AB + 5ARI: 3.1 [2.9]; AB + PT: 3.1 [2.5]). There were no clinically significant differences between MT groups and all showed significant improvement over WW (p Improvements in QoL and symptoms were equivalent across the medical treatments most widely used in real-life practice to manage patients with moderate or severe LUTS. HESr showed an equivalent efficacy to AB and 5ARI with fewer side effects.
metadata.dc.identifier.doi: 10.1007/s11255-015-1206-7
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC4839045.pdf669,96 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons